CN115337469A - Medicinal coating of ligation device and preparation method thereof - Google Patents
Medicinal coating of ligation device and preparation method thereof Download PDFInfo
- Publication number
- CN115337469A CN115337469A CN202210852403.3A CN202210852403A CN115337469A CN 115337469 A CN115337469 A CN 115337469A CN 202210852403 A CN202210852403 A CN 202210852403A CN 115337469 A CN115337469 A CN 115337469A
- Authority
- CN
- China
- Prior art keywords
- parts
- chitosan
- cyanoacrylate
- coating
- ligation device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 39
- 239000011248 coating agent Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 48
- 229920001661 Chitosan Polymers 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001651 Cyanoacrylate Polymers 0.000 claims abstract description 21
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000000202 analgesic effect Effects 0.000 claims abstract description 14
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940072056 alginate Drugs 0.000 claims abstract description 13
- 229920000615 alginic acid Polymers 0.000 claims abstract description 13
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 239000012153 distilled water Substances 0.000 claims abstract description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 13
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003381 stabilizer Substances 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 230000006196 deacetylation Effects 0.000 claims description 6
- 238000003381 deacetylation reaction Methods 0.000 claims description 6
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 claims description 6
- 229950010048 enbucrilate Drugs 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- 229960000905 indomethacin Drugs 0.000 claims description 6
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 claims description 6
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000004005 microsphere Substances 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000001760 anti-analgesic effect Effects 0.000 abstract description 3
- 230000023555 blood coagulation Effects 0.000 abstract description 3
- 125000002091 cationic group Chemical group 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000023597 hemostasis Effects 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000005168 Intussusception Diseases 0.000 description 2
- 208000009443 Vascular Malformations Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a drug coating of a ligation device and a preparation method thereof, wherein the drug coating comprises sodium carboxymethylcellulose, alginate, chitosan, an anti-inflammatory analgesic, polyvinyl alcohol and distilled water; the invention utilizes cyanoacrylate curing process to firmly adhere the microspheres or the medicine on the surface of the coating, chitosan can quickly release the medicine after meeting water, the self cationic property can promote blood coagulation, and meanwhile, the medicine coating is added with anti-inflammatory and analgesic medicine components, so that infection can be prevented, and healing can be promoted.
Description
Technical Field
The invention relates to the technical field of hemostatic drug coatings, in particular to a drug coating of a ligation device and a preparation method thereof.
Background
Gastroscopy has revolutionized the success of minimally invasive surgery as a surgical technique in more and more of the traditional surgical fields, which has become the dominant melody of surgical development worldwide. In the current minimally invasive medical operation, when the operation is carried out in the alimentary canal, the tissues or blood vessels in the alimentary canal inevitably generate bleeding phenomenon, and necessary hemostasis treatment should be carried out in time. In the prior art, suture ligation is generally adopted for hemostasis treatment, but the hemostasis method has the defects of long operation time, small operation space, larger incision assistance requirement and the like. Therefore, the ligation device carried by the clip applier is widely applied to current endoscopic surgery as a highly effective hemostatic closing instrument.
Hemorrhage of digestive tract may be caused by inflammation, mechanical injury, vasculopathy, tumor, etc. of digestive tract, and also may be caused by pathological changes of adjacent organs and systemic diseases affecting digestive tract.
1. Upper gastrointestinal hemorrhage
2. Hemorrhage of the lower and middle digestive tract
(1) Anal canal diseases such as hemorrhoid, anal fissure and anal fistula.
(2) Rectal diseases ulcerative proctitis, tumors (polyps), carcinoids, invasion of the rectum by adjacent malignant tumors or abscesses, infections (bacterial, tuberculous, fungal, viral, parasitic), ischemia, etc.
(3) Colonic disease infections (bacterial, tubercular, fungal, viral, parasitic), ulcerative colitis, diverticulum, tumors (polyps), ischemia and vascular malformations, intussusception, and the like.
(4) Acute hemorrhagic necrotic enteritis of small bowel disease, tuberculosis of the intestine, crohn's disease, diverticulitis or ulcers, intussusception, tumors (polyps), hemangiomas, vascular malformations, ischemia, and the like.
In the prior art, when the ligation device is used with an endoscope for hemostasis of the alimentary tract, the principle of physical locking hemostasis of the ligation device is only applied, and quick hemostasis treatment cannot be timely and accurately performed by matching with hemostatic medicines.
Therefore, there is a need to develop a drug coating for a ligation device to solve this problem.
Disclosure of Invention
The invention aims to provide a drug coating of a ligation device and a preparation method thereof, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a drug coating of a ligation device comprises the following components: sodium carboxymethylcellulose, alginate, chitosan, an anti-inflammatory analgesic, polyvinyl alcohol and distilled water.
Preferably, the feed comprises the following raw materials in parts by weight: 4-6 parts of sodium carboxymethylcellulose, 3-5 parts of alginate, 5-7 parts of chitosan, 2-4 parts of an anti-inflammatory analgesic, 1-3 parts of polyvinyl alcohol and 6-8 parts of distilled water.
Preferably, the medicine coating specifically comprises the following raw materials in parts by weight: 5 parts of sodium carboxymethylcellulose, 4 parts of alginate, 6 parts of chitosan, 3 parts of an anti-inflammatory analgesic, 2 parts of polyvinyl alcohol and 7 parts of distilled water.
Preferably, the chitosan is acid-soluble chitosan with deacetylation degree of more than 95%, and the acid-soluble chitosan is prepared into a chitosan solution by using 0.01-0.5 mol/L diluted acetic acid as a solvent.
Preferably, the anti-inflammatory analgesic agent is indomethacin or ibuprofen.
A preparation method of a drug coating of a ligation device comprises the following steps: cyanoacrylate is sprayed to the ligation head in dry environment, medicine carrying microsphere or medicine is sprayed immediately and fumigated in water vapor for some time to cure the coating.
Preferably, the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate and octyl cyanoacrylate, and contains an acidic stabilizer, and the concentration of the stabilizer is adjustable.
Has the beneficial effects that: the invention has the beneficial effects that: the invention utilizes cyanoacrylate curing process to firmly adhere the microspheres or the medicine on the surface of the coating, chitosan can quickly release the medicine after meeting water, the self cationic property can promote blood coagulation, and meanwhile, the medicine coating is added with anti-inflammatory and analgesic medicine components, so that infection can be prevented, and healing can be promoted.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
A drug coating of a ligation device comprises the following components: sodium carboxymethylcellulose, alginate, chitosan, anti-inflammatory analgesic, polyvinyl alcohol, and distilled water.
In the invention, the feed comprises the following raw materials in parts by weight: 4-6 parts of sodium carboxymethylcellulose, 3-5 parts of alginate, 5-7 parts of chitosan, 2-4 parts of an anti-inflammatory analgesic, 1-3 parts of polyvinyl alcohol and 6-8 parts of distilled water.
In the invention, the medicine coating specifically comprises the following raw materials in parts by weight: 5 parts of sodium carboxymethylcellulose, 4 parts of alginate, 6 parts of chitosan, 3 parts of anti-inflammatory analgesic, 2 parts of polyvinyl alcohol and 7 parts of distilled water.
In the invention, the chitosan is acid-soluble chitosan with deacetylation degree of more than 95%, and the acid-soluble chitosan is prepared into chitosan solution by using 0.01-0.5 mol/L diluted acetic acid as solvent.
In the invention, the anti-inflammatory analgesic agent is indometacin or ibuprofen.
A preparation method of a drug coating of a ligation device comprises the following steps: cyanoacrylate is sprayed to the ligation head in dry environment, medicine carrying microsphere or medicine is sprayed immediately and fumigated in water vapor for some time to cure the coating.
In the invention, the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate and octyl cyanoacrylate, and contains an acidic stabilizer, and the concentration of the stabilizer is adjustable.
Example 1
The drug coating of the ligation device in this embodiment is composed of the following components: 4 parts of sodium carboxymethylcellulose, 3 parts of alginate, 5 parts of chitosan, 2 parts of anti-inflammatory analgesic, 1 part of polyvinyl alcohol and 6 parts of distilled water.
In the invention, the chitosan is acid-soluble chitosan with deacetylation degree of 96%, and the acid-soluble chitosan is prepared into a chitosan solution by using 0.01 mol/L diluted acetic acid as a solvent.
In the invention, the anti-inflammatory analgesic agent is indometacin or ibuprofen.
A preparation method of a drug coating of a ligation device comprises the following steps: cyanoacrylate is sprayed to the ligation head in dry environment, medicine carrying microsphere or medicine is sprayed immediately and fumigated in water vapor for some time to cure the coating.
In the invention, the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate and octyl cyanoacrylate, and contains an acidic stabilizer, and the concentration of the stabilizer is adjustable.
Example 2
The drug coating of the ligation device in the embodiment comprises the following components: 4-6 parts of sodium carboxymethylcellulose, 3-5 parts of alginate, 5-7 parts of chitosan, 2-4 parts of an anti-inflammatory analgesic, 1-3 parts of polyvinyl alcohol and 6-8 parts of distilled water.
In the invention, the chitosan is acid-soluble chitosan with deacetylation degree of more than 99%, and the acid-soluble chitosan is prepared into a chitosan solution by using 0.5 mol/L diluted acetic acid as a solvent.
In the invention, the anti-inflammatory analgesic agent is indometacin or ibuprofen.
A preparation method of a drug coating of a ligation device comprises the following steps: cyanoacrylate is sprayed to the ligation head in dry environment, medicine carrying microsphere or medicine is sprayed immediately and fumigated in water vapor for some time to cure the coating.
In the invention, the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate and octyl cyanoacrylate, and contains an acidic stabilizer with adjustable concentration.
Example 3
The drug coating of the ligation device in this embodiment is composed of the following components: 5 parts of sodium carboxymethylcellulose, 4 parts of alginate, 6 parts of chitosan, 3 parts of an anti-inflammatory analgesic, 2 parts of polyvinyl alcohol and 7 parts of distilled water.
In the invention, the chitosan is acid-soluble chitosan with deacetylation degree of more than 98%, and the acid-soluble chitosan is prepared into a chitosan solution by using 0.2 mol/L diluted acetic acid as a solvent.
In the invention, the anti-inflammatory analgesic agent is indometacin or ibuprofen.
A preparation method of a drug coating of a ligation device comprises the following steps: cyanoacrylate is sprayed to the ligation head in dry environment, medicine carrying microsphere or medicine is sprayed immediately, and the ligation head is fumigated in water vapor for some time to cure the coating.
In the invention, the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate and octyl cyanoacrylate, and contains an acidic stabilizer with adjustable concentration.
The invention utilizes cyanoacrylate curing process to firmly adhere the microspheres or the medicine on the surface of the coating, chitosan can quickly release the medicine after meeting water, the self cationic property can promote blood coagulation, and meanwhile, the medicine coating is added with anti-inflammatory and analgesic medicine components, so that infection can be prevented, and healing can be promoted.
The embodiments described above are preferred embodiments of the present invention, and not all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (7)
1. The drug coating of the ligation device is characterized by comprising the following components: sodium carboxymethylcellulose, alginate, chitosan, an anti-inflammatory analgesic, polyvinyl alcohol and distilled water.
2. The drug coating of the ligation device according to claim 1, comprising the following raw materials in parts by weight: 4-6 parts of sodium carboxymethylcellulose, 3-5 parts of alginate, 5-7 parts of chitosan, 2-4 parts of an anti-inflammatory analgesic, 1-3 parts of polyvinyl alcohol and 6-8 parts of distilled water.
3. The drug coating of the ligation device according to claim 2, comprising the following raw materials in parts by weight: 5 parts of sodium carboxymethylcellulose, 4 parts of alginate, 6 parts of chitosan, 3 parts of anti-inflammatory analgesic, 2 parts of polyvinyl alcohol and 7 parts of distilled water.
4. The drug coating of a ligation device according to claim 3, wherein the chitosan is an acid soluble chitosan with a deacetylation degree of more than 95%, and the acid soluble chitosan is prepared into a chitosan solution by using 0.01-0.5 mol// L of dilute acetic acid as a solvent.
5. The drug coating of a ligation device according to claim 3, wherein the anti-inflammatory analgesic is indomethacin or ibuprofen.
6. A preparation method of a drug coating of a ligation device is characterized by comprising the following steps: and (3) spraying cyanoacrylate on the ligation head in a dry environment, immediately spraying the medicine coating, and fumigating in water vapor for a period of time to realize coating curing.
7. The method of claim 6, wherein the cyanoacrylate comprises one or more of n-butyl cyanoacrylate, isobutyl cyanoacrylate, and octyl cyanoacrylate, and further comprises an acidic stabilizer, wherein the concentration of the stabilizer is adjustable.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210852403.3A CN115337469A (en) | 2022-07-20 | 2022-07-20 | Medicinal coating of ligation device and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210852403.3A CN115337469A (en) | 2022-07-20 | 2022-07-20 | Medicinal coating of ligation device and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115337469A true CN115337469A (en) | 2022-11-15 |
Family
ID=83949881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210852403.3A Pending CN115337469A (en) | 2022-07-20 | 2022-07-20 | Medicinal coating of ligation device and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115337469A (en) |
-
2022
- 2022-07-20 CN CN202210852403.3A patent/CN115337469A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6552115B2 (en) | Adhesive medical products and methods for treating gastrointestinal tract lesions | |
| EP3228331B1 (en) | Biocompatible hemostatic product and preparation method thereof | |
| US20170189573A1 (en) | Novel hemostatic patch and uses thereof | |
| EP3731791B1 (en) | Tissue adherent chitosan material that resists dissolution | |
| EP2549899B1 (en) | Functionalized adhesive for medical devices | |
| JP2010537711A (en) | Surgical hydrogel | |
| CN104717986A (en) | Hydrogel-forming material | |
| KR20100102750A (en) | Compositions and methods for promoting hemostasis and other physiological activities | |
| JP6306198B2 (en) | In vivo administrable microparticles for medical conduits | |
| WO2017028777A1 (en) | Mussel adhesive protein product and application thereof in inhibiting catarrh | |
| WO2006049463A1 (en) | Hemostatic agent internally applied through endoscope and application method thereof | |
| JP2022023110A (en) | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding | |
| CN114159586A (en) | Submucosal injection marker carrier gel for endoscope and application thereof | |
| Kjaergard et al. | Prevention of air leakage by spraying vivostat fibrin sealant after lung resection in pigs | |
| CN115337469A (en) | Medicinal coating of ligation device and preparation method thereof | |
| CN111298188A (en) | Self-curing double-component ion and temperature double-sensitive digestive tract mucosa protective adhesive and application thereof | |
| Gagliardi et al. | Endoscopic application of PuraStat® in the treatment of solitary rectal ulcer syndrome | |
| WO2020182139A1 (en) | Protective gel for gastrointestinal mucosa | |
| WO2017181978A1 (en) | Mussel adhesive protein product and use of same for inhibiting vascular inflammation | |
| KR20190084286A (en) | Bio-tissue pore closure, ulcer protection and vascular embolization therapy sol | |
| US11951229B2 (en) | Liquid hemostatic medical material | |
| US20210251890A1 (en) | Hemostatic compositions and related methods | |
| RU2192256C2 (en) | Method for protecting anastomosis at intestinal resctions | |
| JP2024054923A (en) | Kit for forming crosslinked gelatin, device for producing crosslinked gelatin, method for operating said device, and method for producing crosslinked gelatin | |
| WO2017181371A1 (en) | Mussel adhesive protein product and use of same for inhibiting inflammation of visceral organ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |